Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Investor Presentation (January 2011)
19 slides from Lisata Therapeutics's investor presentation, Jan 24, 2011
Slide 1: NeoStem, Inc. Investor Presentation January 2011
NEOSTEM, INC. (“NBS”) Investor Presentation January 2011
Slide 2: Forward-Looking Statements
x) Forward-Looking Statements Included in this presentation are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. Such forward-locking statements involve known and unknown risks, uncertainties and other factors
Slide 3: About NeoStem
2 About NeoStem NeoStem is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China and a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company. 51% ownership Progenitor C
Slide 4: Acquired 51% of Chinese generic therapeutics company, Suzhou Erye
Acquired 51% of Chinese generic therapeutics company, Suzhou Erye) Location Suzhou China Suzhou Erye +” Vertically-integrated manufacturer of generic antibiotic products and APIs with extensive distribution throughout China — 8 CGMP-certified production lines = Extensive distribution network through
Slide 5: Goals of Suzhou Erye
Goals of Suzhou Erye * Complete relocation to allow doubling of manufacturing capacity; increased revenues expected to flow from eliminating inefficiencies associated with transitioning to new facility - Commercialize pipeline drugs * Continue to develop distribution channels domestically as well as
Slide 6: US Stem Cell Business
US Stem Cell Business planarian Accelerate proprietary cellular therapies and become a single source for collection, storage, manufacturing, therapeutic development and transporter of cells for cell based medicine and regenerative Evolutionary Scale science globally. sstamander Spain buck human Rege
Slide 7: Wound Technology (Worldwide License)
“2 Wound Technology ( Worldwide License) a a Double barreled syringe Back wound after surgery ‘Spraying adult stem Wound completely healed te spray adult stem cells” to Remove skin cancer cells into the wound ‘ofter 7 months Baseline ‘During 3" Application Almost Healed at 3months Complete Closure a
Slide 8: Goals of US Cell Therapy Business
Goals of US Cell Therapy Business « Grow revenues from process and assay development, manipulation, cryopreservation, storage, manufacturing and distribution « Expand contract cGMP manufacturing for other cell therapy centers, academic, institutions and companies using China facility in development
Slide 9: Validating Partnerships
Validating Partnerships Academic Collaborators of NeoStem for VSEL Development + Sponsored research agreement with University of California-Davis + Sponsored research agreement with the Schepens Eye Research Institute, an affiliate of Harvard + Sponsored research agreement with University of Louisvi
Slide 10: NeoStem's China Affiliated Entities
2 NeoStem’s China Affiliated Entities => 1.) Network of Hospitals delivering NeoStem’s Asia licensed Adult Stem Cell technology for Orthopedics using MSCs 1.) Wendeng Hospital - Launched June 2010 2.) Shijianzhuag — Third Hospital signed December 2010 3.) A third hospital in Tianjin expected to sign
Slide 11: Progressive Stem Cell Environment in China
2 Progressive Stem Cell Environment in China © Favorable clinical and regulatory environment - Greater receptivity toward advanced therapeutics such as stem cell therapy - Actively seeking innovative technologies and therapies from the U.S. « Large and rapidly growing Chinese health care market goin
Slide 12: Licensed Proprietary Delivery Technology in China
2 Licensed Proprietary Delivery Technology in China Goal: Developing cellular therapy platform in China to generate revenues today and serve as a vehicle for expansion in the future Proprietary Technology Cells Used Currently Potential Future Indication Advancements Orthopedics Mscs VSELs™ Technolog
Slide 13: Summary of NeoStem Business Strategy
2 Summary of NeoStem Business Strategy Integrated Components build value with multiple revenue sources Develop comprehensive cord and adult stem cell banking business at cGMP quality Recurring revenue from annual storage fees Leverage expertise to cost effectively and efficiently produce regulatory
Slide 14: NeoStem Management Team
Robin Smith, MD MBA (CEO & Chairman of the Board sian Zhang “General Manager, Suzhou Erve Pharmaceuticals Co, Led {an Zhang, PhO MBA President and Managing Director ‘NeaStem (China), tne Larry May (Chief Financial Officer Catherine Vaczy, Esq VP and General Counsal ‘Alan Haris, IMD PhD FAC FRCP VP,
Slide 15: NeoStem Board of Directors
Se) Si Robin Smith, MD, MBA CEO & Chairman of the Board + Eric Wei . Managing Partner, RimAsia Capital Partners Mingsheng Shi . Chairman of the Boardof + Suzhou Erye Pharmaceutical Steven Myers . (ndependent) 6 Drew Bernstein, CPA . (independent) 6 Richard Berman : (independent) é Edward Geehr, MD .
Slide 16: Capitalization Table
Capitalization Table NeoStem Capitalization Table Capitalization (Common Share Equivalent in 000s) Shares Outstanding % Outstanding ‘Common Stock 74,890 62.7% Total Preferred Shares (common share equivalents) 5,300" 45% Total Warrants (average exercise price $2.91) 24,844 20.8% Total Options (averag
Slide 17: Historical Income Statement and Balance Sheet
Historical Income Statement ($ 000’s) Balance Sheet ($ 000's) ‘9 Months Ending 'As of 9130010 9130/10 Revenue Cash & equivalents $ 4067 Pharmaceuticals $ 51,500 Current assets $ 28,258 ‘Stem cell and others zine Total assets $116,971 Fetalierenvee S210 Current liabilities $ 20570 Se GA Total liabili
Slide 18: NeoStem's Unique Business Model
2 NeoStem’s Unique Business Model Created a platform that has short term and long term value drivers Uses profitable pharmaceutical business to offset certain costs associated with development of stem cell therapeutics Blends regulatory environments to generate revenues from stem cell therapies in C
Slide 19: Contact Information
Contact Information NeoStem, Inc. Robin Smith, MD, MBA Chairman & CEO Phone: (212) 584-4174 Email: rsmith@neostem.com http://www.neostem.com 19